PARP1 and small cell lung carcinoma: SCLC-P (POU2F3-high): SCLC-P is most sensitive to cisplatin treatment and shows sensitivity to poly-ADP ribose polymerase (PARP) inhibitors and anti-metabolites, such as anti-folates, as well as aurora kinase inhibitors [6,31,62].